OTCMKTS:INCPF InnoCare Pharma (INCPF) Stock Price, News & Analysis $1.85 0.00 (0.00%) As of 10/6/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and Trends About InnoCare Pharma Stock (OTCMKTS:INCPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get InnoCare Pharma alerts:Sign Up Key Stats Today's Range$1.85▼$1.8550-Day Range$1.55▼$1.8552-Week Range$1.55▼$2.31VolumeN/AAverage Volume550 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview InnoCare Pharma Limited is a China-based biopharmaceutical company focused on discovering, developing and commercializing therapies for cancer and autoimmune diseases. The company uses small-molecule and biologic drug development technologies to target diseases with significant unmet medical needs. Its principal commercial product is orelabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor developed for the treatment of certain B-cell malignancies. Orelabrutinib has received approval in China for indications including relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukemia or small lymphocytic lymphoma. InnoCare also has a pipeline of investigational therapies addressing hematologic cancers, solid tumors and autoimmune conditions. Founded in 2015, InnoCare conducts research and development activities in China and has expanded its international presence through collaborations and development efforts in overseas markets. The company is led by co-founder and Chief Executive Officer Dr. Jasmine Cui, who has a background in pharmaceutical research and drug development.AI Generated. May Contain Errors. Read More Receive INCPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InnoCare Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INCPF Stock News HeadlinesChina's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billionSeptember 23, 2026 | reuters.comInnoCare Pharma Limited (INCPF) Q2 2026 Earnings Call TranscriptAugust 24, 2026 | seekingalpha.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 7 at 1:00 AM | Stansberry Research (Ad)InnoCare Pharma Sets Board Meeting to Approve 2026 Interim ResultsAugust 11, 2026 | tipranks.comChina's Innocare's psoriasis drug meets main goal in late-stage trialJuly 27, 2026 | reuters.comInnoCare Shareholders Approve All Resolutions at 2026 AGMJune 16, 2026 | tipranks.comPhase IIb Study Results of InnoCare's Orelabrutinib in Patients with SLE Presented at 2026 EULARJune 4, 2026 | globenewswire.comASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML ReleasedJune 2, 2026 | globenewswire.comSee More Headlines INCPF Stock Analysis - Frequently Asked Questions How have INCPF shares performed this year? InnoCare Pharma's stock was trading at $2.05 on January 1st, 2026. Since then, INCPF shares have decreased by 9.8% and is now trading at $1.85. How do I buy shares of InnoCare Pharma? Shares of INCPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/07/2026Next Earnings (Estimated)10/27/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:INCPF CIKN/A Webwww.innocarepharma.com Phone861066609999FaxN/AEmployees1,089Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:INCPF) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InnoCare Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share InnoCare Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
